Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.02 USD | -0.20% | -10.04% | -19.94% |
Mar. 13 | Transcript : ScPharmaceuticals Inc., Q4 2023 Earnings Call, Mar 13, 2024 | |
Mar. 13 | ScPharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 40.03M | Sales 2025 * | 97.75M | Capitalization | 181M |
---|---|---|---|---|---|
Net income 2024 * | -58M | Net income 2025 * | -26M | EV / Sales 2024 * | 4.53 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.86 x |
P/E ratio 2024 * |
-3.41
x | P/E ratio 2025 * |
-8.16
x | Employees | 136 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.56% |
Latest transcript on scPharmaceuticals Inc.
1 day | +2.44% | ||
1 week | -9.86% | ||
Current month | -16.45% | ||
1 month | -19.13% | ||
3 months | -21.41% | ||
6 months | -28.55% | ||
Current year | -19.78% |
Managers | Title | Age | Since |
---|---|---|---|
John Tucker
CEO | Chief Executive Officer | 61 | 16-12-31 |
Rachael Nokes
DFI | Director of Finance/CFO | 49 | 14-08-31 |
John Mohr
CTO | Chief Tech/Sci/R&D Officer | - | 17-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 13-12-31 | |
Klaus Veitinger
BRD | Director/Board Member | 62 | 17-11-20 |
John Tucker
CEO | Chief Executive Officer | 61 | 16-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 36 M€ | +4.74% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 5.02 | -0.20% | 110 060 |
24-03-27 | 5.03 | +2.44% | 229,540 |
24-03-26 | 4.91 | +1.03% | 299,212 |
24-03-25 | 4.86 | -6.00% | 664,203 |
24-03-22 | 5.17 | -3.90% | 206,239 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.78% | 181M | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.75% | 210B | |
+1.38% | 210B | |
-6.81% | 201B | |
-3.51% | 157B |